Low PPP2R2A Expression and CHK1 Inhibition in Ovarian Cancer
Author Information
Author(s): Qiu Zhaojun, Sigh Deepika, Liu Yujie, Prasad Chandra B., Bean Nichalos, Yan Chunhong, Li Zaibo, Zhang Xiaoli, Narla Goutham, DiFeo Analisa, Wang Qi-En, Zhang Junran
Primary Institution: The Ohio State University
Hypothesis
Does PPP2R2A deficiency enhance the sensitivity of high-grade serous ovarian cancer (HGSOC) to CHK1 inhibition?
Conclusion
PPP2R2A deficiency increases sensitivity to CHK1 inhibitors in HGSOC, suggesting it as a potential biomarker and therapeutic target.
Supporting Evidence
- PPP2R2A deficiency is linked to increased sensitivity to CHK1 inhibitors.
- Low expression of PPP2R2A correlates with poor prognosis in ovarian cancer.
- CHK1 inhibition shows promise in treating HGSOC with PPP2R2A deficiency.
Takeaway
If a certain protein is low in ovarian cancer cells, those cells are more likely to be hurt by a specific cancer treatment.
Methodology
The study involved treating HGSOC cells with a CHK1 inhibitor and assessing cell growth through in vitro and in vivo assays.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website